Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis

被引:7
|
作者
Fan, Caibin [1 ]
Lu, Wei [2 ]
Li, Kai [1 ]
Zhao, Chunchun [1 ]
Wang, Fei [1 ]
Ding, Guanxiong [3 ]
Wang, Jianqing [1 ]
机构
[1] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou Municipal Hosp, Gusu Sch,Dept Urol, 26 Daoqian Rd, Suzhou 215000, Jiangsu, Peoples R China
[2] Suzhou Vocat Hlth Coll, Sch Nursing, Suzhou, Jiangsu, Peoples R China
[3] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune infiltration; metastatic castration resistant prostate cancer (mCRPC); RNA sequencing; bioinformatics analysis; immunotherapy; DIFFERENTIAL EXPRESSION ANALYSIS; BREAST-CANCER; IMMUNOTHERAPY; SURVIVAL; INTERLEUKIN-2; PROLIFERATION; ENZALUTAMIDE; ANTAGONISTS; INHIBITION; DIAGNOSIS;
D O I
10.3233/CBM-203222
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal stage of prostate cancer and the main cause of morbidity and mortality, which is also a potential target for immunotherapy. METHOD: In this study, using the Approximate Relative Subset of RNA Transcripts (CIBERSORT) online method, we analysed the immune cell abundance ratio of each sample in the mCRPC dataset. The EdgeR (an R package) was used to classify differentially expressed genes (DEGs). Using the Database for annotation, visualisation and interactive exploration (DAVID) online method, we performed functional enrichment analyses. STRING online database and Cytoscape tools have been used to analyse protein-protein interaction (PPI) and classify hub genes. RESULTS: The profiles of immune infiltration in mCRPC showed that Macrophages M2, Macrophages M0, T cells CD4 memory resting, T cells CD8 and Plasma cells were the main infiltration cell types in mCRPC samples. Macrophage M0 and T cell CD4 memory resting abundance ratios were correlated with clinical outcomes. We identified 1102 differentially expressed genes (DEGs) associated with the above two immune cells to further explore the underlying mechanisms. Enrichment analysis found that DEGs were substantially enriched in immune response, cell metastasis, and metabolism related categories. We identified 20 hub genes by the protein-protein interaction network analysis. Further analysis showed that three critical hub genes, CCR5, COL1A1 and CXCR3, were significantly associated with prostate cancer prognosis. CONCLUSION: Our findings revealed the pattern of immune cell infiltration in mCRPC, and identified the types and genes of immune cells correlated with clinical outcomes. A new theoretical basis for immunotherapy may be given by our results.
引用
收藏
页码:363 / 377
页数:15
相关论文
共 50 条
  • [21] Identification of genes associated with castration-resistant prostate cancer by gene expression profile analysis
    Huang, Chui Guo
    Li, Feng Xi
    Pan, Song
    Xu, Chang Bao
    Dai, Jun Qiang
    Zhao, Xing Hua
    MOLECULAR MEDICINE REPORTS, 2017, 16 (05) : 6803 - 6813
  • [22] Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
    Perez-Navarro, Enrique
    Conteduca, Vincenza
    Funes, Juan M.
    Dominguez, Jose I.
    Martin-Serrano, Miguel
    Cremaschi, Paolo
    Piedad Fernandez-Perez, Maria
    Gordoa, Teresa Alonso
    Font, Albert
    Vazquez-Estevez, Sergio
    Gonzalez-del-Alba, Aranzazu
    Wetterskog, Daniel
    Mellado, Begona
    Fernandez-Calvo, Ovidio
    Jose Mendez-Vidal, Maria
    Angel Climent, Miguel
    Duran, Ignacio
    Gallardo, Enrique
    Rodriguez Sanchez, Angel
    Santander, Carmen
    Isabel Saez, Maria
    Puente, Javier
    Tudela, Julian
    Marinas, Cecilia
    Jose Lopez-Andreo, Maria
    Castellano, Daniel
    Attard, Gerhardt
    Grande, Enrique
    Rosino, Antonio
    Botia, Juan A.
    Palma-Mendez, Jose
    De Giorgi, Ugo
    Gonzalez-Billalabeitia, Enrique
    CANCERS, 2024, 16 (14)
  • [23] Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer
    Oshima, Masashi
    Takayama, Ken-ichi
    Yamada, Yuta
    Kimura, Naoki
    Kume, Haruki
    Fujimura, Tetsuya
    Inoue, Satoshi
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [24] Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer
    Masashi Oshima
    Ken-ichi Takayama
    Yuta Yamada
    Naoki Kimura
    Haruki Kume
    Tetsuya Fujimura
    Satoshi Inoue
    Scientific Reports, 13 (1)
  • [25] Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods
    Wang, Ji-li
    Wang, Yan
    Ren, Guo-ping
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2020, 21 (03): : 246 - 255
  • [26] Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
    Wu, Zixi
    Zhang, Junbiao
    Li, Le
    Wang, Zhihua
    Yang, Chunguang
    ANNALS OF MEDICINE, 2025, 57 (01)
  • [27] HEALTH-RELATED QUALITY OF LIFE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CRITICAL LITERATURE REVIEW
    Nussbaum, N.
    Dorff, T.
    Abernethy, A.
    Dolan, C.
    Flanders, S.
    Oestreicher, N.
    George, D. J.
    VALUE IN HEALTH, 2015, 18 (03) : A211 - A211
  • [28] Abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Mostaghel, Elahe A.
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 39 - 51
  • [29] Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Hussain, Maha
    Mateo, Joaquin
    Fizazi, Karim
    Saad, Fred
    Shore, Neal
    Sandhu, Shahneen
    Chi, Kim N.
    Sartor, Oliver
    Agarwal, Neeraj
    Olmos, David
    Thiery-Vuillemin, Antoine
    Twardowski, Przemyslaw
    Roubaud, Guilhem
    Ozguroglu, Mustafa
    Kang, Jinyu
    Burgents, Joseph
    Gresty, Christopher
    Corcoran, Claire
    Adelman, Carrie A.
    de Bono, Johann
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (24): : 2345 - 2357
  • [30] Trial design for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Fleming, Mark T.
    Hutson, Thomas E.
    Galsky, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3647 - 3648